Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine, mitoxantrone, and
cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more cancer cells. Colony stimulating factors, such as G-CSF, may
increase the number of immune cells found in bone marrow or peripheral blood and may help the
immune system recover from the side effects of combination chemotherapy. It is not yet known
whether giving combination chemotherapy alone is more effective than combination chemotherapy
together with G-CSF in treating patients with chronic lymphocytic leukemia.
PURPOSE: This randomized phase III trial is studying giving combination chemotherapy together
with G-CSF to see how well it works compared to giving combination chemotherapy alone in
treating patients with relapsed stage I, stage II, stage III, or stage IV chronic lymphocytic
leukemia.